Salinas-Casado Jesús, Méndez-Rubio Santiago, Esteban-Fuertes Manuel, Gómez-Rodríguez Antonio, Vírseda-Chamorro Miguel, Luján-Galán Marcos, Iglesias-García Carlos, Rituman Grupo
Servicio de Urología. Hospital Clínico San Carlos. Madrid. España.
Servicio de Urología. Hospital Universitario Sanitas La Moraleja. Madrid. España.
Arch Esp Urol. 2020 Jul;73(6):491-498.
To compare the efficacy and safety in the prophylasis of urinary tract infections (UTIs) with a food supplement that contains D-mannose like active ingredient (Manosar®), in comparison to another preparation in which the active ingredient are the proanthocyanidins (PAC), both of them, in prolonged released, after, they was administered for 24 weeks.
A multicenter, randomized and double blind experimental study was carried out. 283 women with a history of recurrent UTIs without evidence of complication were included. They were randomized 1: 1 in two groups. In one group, 1 oral sachet of Manosar® a day was administered, and in the other group 1 oral sachet of a compound of 240 mg of continuous-release PAC. Prior to inclusion in the study, the episode of UTI was confirmed at least by the clinical symptoms and positivity of the Combur test.
Valid data were obtained from 184 patients with an average age of 49.5 years: 90 received Manosar® and 94 isolated PAC. A total of 72 patients suffered an UTI due to E.coli: 25 patients in the arm with Manosar® versus 47 patients in the isolated PAC group, this difference being statistically significant (p=0.002). The free time of new UTI recurrences was 98.6 days in the group treated with Manosar® and 84.6 days in the group with isolated PAC.
The oral taking of a daily sachet of Manosar® is effective and safe in preventing recurrent UTIs in women, being superior to the oral taking of isolated PAC.
比较一种含有D-甘露糖作为活性成分(甘露糖宝®)的食品补充剂与另一种以原花青素(PAC)为活性成分的制剂在预防尿路感染(UTIs)方面的疗效和安全性,两种制剂均为缓释制剂,给药24周后进行比较。
开展一项多中心、随机、双盲实验研究。纳入283例有复发性UTIs病史且无并发症证据的女性。她们被1:1随机分为两组。一组每天口服1袋甘露糖宝®,另一组口服1袋含240mg缓释PAC的化合物。在纳入研究前,至少通过临床症状和尿隐血试验阳性确认UTIs发作。
从184例平均年龄49.5岁的患者中获得有效数据:90例接受甘露糖宝®,94例接受单独的PAC。共有72例患者因大肠杆菌感染UTIs:甘露糖宝®组25例,单独PAC组47例,差异有统计学意义(p = 0.002)。甘露糖宝®治疗组新UTIs复发的自由时间为98.6天,单独PAC组为84.6天。
女性每天口服1袋甘露糖宝®在预防复发性UTIs方面有效且安全,优于口服单独的PAC。